WallStreetZenWallStreetZen

NASDAQ: CFRX
Contrafect Corp Stock

$0.07-0.02 (-22.22%)
Updated Jan 27, 2023
CFRX Price
$0.07
Fair Value Price
$0.21
Market Cap
$2.71M
52 Week Low
$0.06
52 Week High
$4.54
P/E
-0.05x
P/B
-0.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$59.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-8.42
Operating Cash Flow
-$45M
Beta
0.98
Next Earnings
Mar 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CFRX Overview

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CFRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CFRX ($0.07) is undervalued by 67.25% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CFRX ($0.07) is significantly undervalued by 67.25% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CFRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CFRX due diligence checks available for Premium users.

Be the first to know about important CFRX news, forecast changes, insider trades & much more!

CFRX News

Valuation

CFRX fair value

Fair Value of CFRX stock based on Discounted Cash Flow (DCF)
Price
$0.07
Fair Value
$0.21
Undervalued by
66.77%
CFRX ($0.07) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CFRX ($0.07) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CFRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CFRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.05x
Industry
12.89x
Market
23.59x

CFRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.87x
Industry
5.18x

CFRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$17.1M
Profit Margin
0%
CFRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$23.0M
Liabilities
$26.1M
Debt to equity
-8.42
CFRX's short-term liabilities ($23.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CFRX's short-term assets ($20.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CFRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CFRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.7M
Investing
$4.8M
Financing
$0.0
CFRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CFRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CFRX$2.71M-25.00%-0.05x-0.87x
SPRC$2.77M-3.03%1.04x1.12x
MTP$2.62M+1.37%-0.78x0.31x
ALLR$2.49M+4.29%-0.05x1.72x
CNSP$3.00M-6.60%-0.21x0.36x

Contrafect Stock FAQ

What is Contrafect's quote symbol?

NASDAQ: CFRX) Contrafect trades on the NASDAQ under the ticker symbol CFRX. Contrafect stock quotes can also be displayed as NASDAQ: CFRX.

If you're new to stock investing, here's how to buy Contrafect stock.

What is the 52 week high and low for Contrafect (NASDAQ: CFRX)?

(NASDAQ: CFRX) Contrafect's 52-week high was $4.54, and its 52-week low was $0.06. It is currently -98.48% from its 52-week high and 9.52% from its 52-week low.

How much is Contrafect stock worth today?

(NASDAQ: CFRX) Contrafect currently has 39,332,721 outstanding shares. With Contrafect stock trading at $0.07 per share, the total value of Contrafect stock (market capitalization) is $2.71M.

Contrafect stock was originally listed at a price of $52.10 in Sep 12, 2014. If you had invested in Contrafect stock at $52.10, your return over the last 8 years would have been -99.87%, for an annualized return of -56.32% (not including any dividends or dividend reinvestments).

How much is Contrafect's stock price per share?

(NASDAQ: CFRX) Contrafect stock price per share is $0.07 today (as of Jan 27, 2023).

What is Contrafect's Market Cap?

(NASDAQ: CFRX) Contrafect's market cap is $2.71M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Contrafect's market cap is calculated by multiplying CFRX's current stock price of $0.07 by CFRX's total outstanding shares of 39,332,721.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.